1. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
- Author
-
Yi Lu, Zhongjian Chen, Wei Wu, Pijush Kumar Paul, Quangang Zhu, and Jianping Qi
- Subjects
CPP, cell penetrating peptide ,RGD, Arg-Gly-Asp ,FA - Folic acid ,DDVAP, desmopressin acetate ,GRAS, generally recognized as safe ,PLA, poly(latic acid) ,EPR, electron paramagnetic resonance ,pI, isoelectric point ,PLGA, poly(lactic-co-glycolic acid) ,MSNs, mesoporous silica nanoparticles ,Review ,FcRn, Fc receptor ,GIPET, gastrointestinal permeation enhancement technology ,SGC, sodium glycocholate ,Bioinformatics ,FA, folic acid ,EDTA, ethylene diamine tetraacetic acid ,0302 clinical medicine ,Medicine ,MCT-1, monocarborxylate transporter 1 ,General Pharmacology, Toxicology and Pharmaceutics ,health care economics and organizations ,PBPK, physiologically based pharmacokinetics ,STC, sodium taurocholate ,0303 health sciences ,IBD, inflammatory bowel disease ,pHPMA, N-(2-hydroxypropyl)methacrylamide ,PVA, poly vinyl alcohol ,Enzyme inhibitor ,HPMCP, hydroxypropyl methylcellulose phthalate ,CaP, calcium phosphate ,GI, gastrointestinal ,PGA, poly-γ-glutamic acid ,Oral delivery ,HBsAg, hepatitis B surface antigen ,TMC, N-trimethyl chitosan ,Permeation enhancer ,LBNs, lipid-based nanoparticles ,030220 oncology & carcinogenesis ,SNEDDS, self-nanoemulsifying drug delivery systems ,Parenteral route ,SDC, sodium deoxycholate ,DCs, dendritic cells ,SIF, simulated intestinal fluids ,NLCs, nanostructured lipid carriers ,Stability ,VB12, vitamin B12 ,WGA, wheat germ agglutinin ,education ,High selectivity ,RM1-950 ,EPD, empirical phase diagrams ,Clinical ,03 medical and health sciences ,PPs, proteins and peptides ,TfR, transferrin receptors ,CAGR, compound annual growth ,LMWP, low molecular weight protamine ,SAR, structure–activity relationship ,Tf, transferrin ,IBD - Inflammatory bowel disease ,sCT, salmon calcitonin ,sc, subcutaneous ,GLP-1, glucagon-like peptide 1 ,Tf transferrin ,030304 developmental biology ,PCL, polycarprolacton ,PCA, principal component analysis ,ILs, ionic liquids ,business.industry ,Proteins ,NAC, N-acetyl-l-cysteine ,UEA1, ulex europaeus agglutinin 1 ,SLNs, solid lipid nanoparticles ,PAA, polyacrylic acid ,SGF, simulated gastric fluids ,DTPA, diethylene triamine pentaacetic acid ,GALT, gut-associated lymphoid tissue ,CD - Crohn's disease ,Clinical trial ,FDA, U.S. Food and Drug Administration ,UC, ulcerative colitis ,SNAC, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate ,COPD, chronic obstructive pulmonary disease ,RTILs, room temperature ionic liquids ,TAT, trans-activating transcriptional peptide ,UC - Ulcerative colitis ,BSA, bovine serum albumin ,CD, Crohn's disease ,Therapeutics. Pharmacology ,ASBT, apical sodium-dependent bile acid transporter ,Peptides ,business - Abstract
Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Some new technologies have been developed under clinical trials and even on the market. This review summarizes the history, the physiological barriers and the overcoming approaches, current clinical and preclinical technologies, and future prospects of oral delivery of PPs., Graphical abstract The current strategies for improving oral absorption of proteins and peptides (PPs) include stabilization, absorption enhancement and mucus-related technologies. Most of marketed oral PP products employ two or more strategies.Image 1
- Published
- 2021
- Full Text
- View/download PDF